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OBJECTIVES We examined whether selective cyclooxygenase-2 (COX-2) inhibition in apolipoprotein-E
(apoE) deficient mice reduces cytomegalovirus (CMV) replication, and determined whether
COX-2 anti-inflammatory activity leads to decreased atherosclerosis.
BACKGROUND Evidence suggests that CMV infection contributes to atherosclerosis and that this occurs in
part through inflammatory mechanisms. Cyclooxygenase-2 inhibitors are potent anti-
inflammatory agents. They also inhibit CMV replication in vitro.
METHODS The apoE deficient mice were either treated or not treated with a selective COX-2 inhibitor,
and either infected or not infected with CMV. Viral deoxyribonucleic acid load in salivary
glands was determined by quantitative polymerase chain reaction. Atherosclerotic lesion
analysis was performed by standard methods.
RESULTS In vivo COX-2 inhibition, unexpectedly increased viral load: in the CMV-infected animals
viral load was 2.58  1.0 in the nontreated group, 4.74  1.38 in the group treated with 12
mg/kg/day MF-tricyclic, and 6.51  1.64 in the group treated with 24 mg/kg/day
MF-tricyclic (p trend  0.050). This increased viral load was paralleled by increased
anti-CMV antibody titers. Most surprisingly, COX-2 inhibition significantly increased early
atherosclerotic lesion area, independent of viral infection.
CONCLUSIONS Our study demonstrates that selective inhibition of COX-2 in vivo increases viral load. The
finding that inhibition of COX-2 increases atherosclerosis development in apoE deficient
mice suggests, unexpectedly, that this enzyme exerts antiatherosclerosis activity, at least in this
model. (J Am Coll Cardiol 2003;41:1812–9) © 2003 by the American College of
Cardiology Foundation
Evidence suggests that infection with any of several patho-
gens, including cytomegalovirus (CMV), contributes to
atherosclerosis (1–3), and that this occurs in part through
inflammatory mechanisms (1,2). Strong evidence suggesting
a causal role of CMV in atherogenesis is provided by the
demonstration that CMV infection causes atherosclerosis
progression in a murine model of atherosclerosis (4–6).
See page 1820
We previously demonstrated that CMV infection of
human coronary artery smooth muscle cells (SMCs) gener-
ates intracellular reactive oxygen species (ROS) (7). This is
undoubtedly part of the host’s defense response, as ROS are
essential for nuclear translocation of nuclear factor kappa-B
(NFB), where it transactivates many genes involved in
inflammatory and immune responses (8). However, CMV
also requires NFB for transactivating its own genes. Its
major immediate early promoter has four NFB binding
sites that, when activated by NFB, initiate expression of
the downstream viral genes essential for viral replication (9).
We further explored the pathway by which CMV gen-
erates ROS. We found that CMV activates a pertussis
toxin-sensitive G-protein–coupled cascade, leading to a
cyclooxygenase-2 (COX-2)–dependent increase in ROS
through arachidonic acid release and metabolism via
mitogen-activated protein kinase-dependent stimulation of
phospholipase A2 (10). These studies also confirmed the
importance of the cyclooxygenase system in the viral path-
way of cell activation. Thus, COX-2 inhibition, either with
the nonselective COX inhibitors aspirin and indomethecin,
or with the selective COX-2 inhibitor NS-398, diminished
CMV-induced ROS generation, thereby preventing NFB
activation (11). Moreover, aspirin prevented in vitro CMV
replication in human coronary artery SMCs (11). Therefore,
we proposed that COX-2 might be a therapeutic target: that
its inhibition would diminish viral replication in vivo,
thereby inhibiting any contribution of the virus to athero-
genesis.
The COX-2 inhibitory drugs are also potent anti-
inflammatory agents (12). Because inflammation plays a
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central role in atherogenesis (13), a compelling case can be
made for such drugs inhibiting atherosclerosis progression
independent of any antiviral effect. The purpose of the
present investigation was to determine in a mouse model of
atherosclerosis the validity of two hypotheses: 1) selective
COX-2 inhibition, through the mechanisms responsible for
its in vitro antiviral effects, reduces CMV replication in vivo;
and 2) selective COX-2 inhibition, through its anti-
inflammatory activity, decreases atherosclerosis develop-
ment independent of infection.
METHODS
Animals and CMV infection. The study protocol was
approved by the Medstar Research Institute Animal Care
and Use Committee, in accordance with the guide for the
care and use of laboratory animals (NIH publication No.
85-23, revised 1996).
The apolipoprotein-E (apoE) deficient mice were pur-
chased from Jackson Laboratory (Bar Harbor, Maine). All
mice were housed in microisolator cages in a pathogen-free
facility and allocated into six groups (Table 1). Mouse CMV
(Smith strain, VR-1399, American Type Culture Collec-
tion [ATCC], Manassas, Virginia) propagated in mouse
fibroblast SC-1 cells (ATCC). Eight week-old mice (groups
3 to 6) were injected intraperitoneally either with 5  104
PFU mouse CMV or with the supernatant of uninfected
SC-1 cells (ATCC). Injections were given 48 h after
initiation of the feeding protocol. Mice allocated to groups
1 and 2 did not receive the virus. At 11 weeks of age salivary
glands, spleens, and blood were collected and serum was
obtained. Samples were stored at 80°C.
Drug. We used the selective COX-2 inhibitor MF-
tricyclic [3-(3, 4-difluorophenyl)-4-(4-(methylsulfonyl)
phenyl)-2-(5H)-furanone]. This drug has no significant
anti-COX-1 activity at clinically effective concentrations
(14). Drug-free chow and sterile mixture of drug in mouse
chow were obtained from Merck Pharmaceuticals (Merck
Frosst Canada and Co., Kirkland, Canada) in two drug
concentrations: 0.01334% (w/w) and 0.0067% (w/w); fresh
chow was administered daily.
Mice were fed ad lib with drug-containing chow or
control chow. Mice in all six groups were started on this
feeding protocol simultaneously. The feeding protocol was
continued for three weeks, when mice were sacrificed. Food
intake and body weight were monitored weekly and the
drug doses calculated accordingly. Serum samples were
shipped to Merck for drug levels testing.
Polymerase chain reaction (PCR) analysis. Samples were
coded so that the analysis was done blindly as to sample
source.
GENOMIC DEOXYRIBONUCLEIC ACID (DNA) EXTRAC-
TION. DNA was isolated from mouse salivary glands (Gen-
tra Systems, Minneapolis, Minnesota).
TAQMAN ANALYSIS. Target gene—mouse CMV IE1 exon
4, accession number M11788, TaqMan probe and primers
were selected using Primer Express software (PerkinElmer
Life Sciences Inc. Beltsville, Maryland) and were synthe-
sized at BioServe Biotechnologies Ltd. (Laurel, Maryland).
Primer and probe optimizations were performed at 60°C.
Mouse CMV (TET-labeled probe) and apoB (6FAM-
labeled probe) constitutive gene were analyzed alone. All
TaqMan reactions were performed in 15 l volumes using
2 Universal Master Mix (PerkinElmer), 6.25 pmol of each
primer, 6.25 pmol of mouse CMV probe, and 1 l of 100
ng/l DNA. The “real time” amplification program con-
sisted of 50°C for 2 min (AmpErase UNG cleavage step),
95°C for 10 min (activation of AmpliTaq Gold step), and
then 40 cycles of 95°C for 15 s followed by 60°C for 1 min.
A standard curve was generated using 10-fold dilutions of
SC-1 cells (ATCC) infected with mouse CMV. The upper
and lower limits of DNA concentrations used were 100
ng/l and 100 fg/l.
Abbreviations and Acronyms
apoE  apolipoprotein-E
CMV  cytomegalovirus
COX  cyclooxygenase
DNA  deoxyribonucleic acid
IFN  interferon-gamma
IgG  immunoglobulin-G
IL  interleukin
NFB  nuclear factor kappa-B
PCR  polymerase chain reaction
PG  prostaglandin
ROS  reactive oxygen species
SMCs  smooth muscle cells
TNF  tumor necrosis factor-alpha
Table 1. Mice Allocation
Group
(n) Inoculum
Drug
(mg/kg/day)
PCR
(n)
Serology
(n)
Lesion
Analysis (n)
1 (16) None None None None 11
2 (16) None 12 None None 11
3 (17) Sham None 17 17 12
4 (17) CMV None 17 17 12
5 (17) CMV 12 17 17 12
6 (17) CMV 24 17 17 12
CMV  cytomegalovirus; PCR  polymerase chain reaction.
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Serology. Anti-mouse CMV immunoglobulin G (IgG)
antibody titer was determined in mouse serum by using an
anti-mouse CMV IgG enzyme-linked immunosorbent as-
say kit (Charles River Laboratories, Wilmington, Massa-
chusetts). The presence or absence of anti-CMV IgG was
determined by the value (optical density sample  optical
density issue control) divided by 0.13. A value above 3 was
regarded as positive. The positive sample was further diluted
to 1:60, 1:500, 1:1,000, 1:2,000, and 1:3,000. The antibody
titer was considered to be the highest dilution at which the
sample was reading positive.
Cytokine concentrations. Interferon-gamma (IFN), tu-
mor necrosis factor-alpha (TNF), and interleukin-6 (IL-6)
concentrations in mouse serum were determined by using
mouse ELISA kits (Biosource International, Camarillo,
California). All assays were performed in duplicate. Mini-
mal detectable levels of IL-6, IFN, and TNF were 3.0,
1.0, and 3.0 pg/ml, respectively.
Quantification of atherosclerotic lesions. Hearts were
coded so analysis was performed blindly. Lesions were
analyzed as described (15). Hearts were fixed in 10%
buffered formalin and embedded in 5%, 10%, and then 25%
gelatin. Frozen sections (10-m) of the aortic sinus were cut
and then stained using oil red O and hematoxylin and
counterstained with light green. Five sections per mouse
were analyzed for lesions. Area analysis was completed using
Spot ImagePro Driver software (Diagnostic Instruments).
Cholesterol levels. Serum samples, collected at time of
killing, were individually evaluated for cholesterol by
Cholesterol-SL-Assay, a 4-aminoantipyrine-based enzy-
matic assay (Diagnostic Chemical Limited, Oxford, Con-
necticut).
Statistical analysis. Data are given as mean  SEM.
Comparisons between multiple experimental groups were
made by one-way analysis of variance or Kruskal-Wallis
test, as appropriate. Comparisons between two experimental
groups were made by Student t test (two-tailed). Values of
p0.05 were considered statistically significant. Polymerase
chain reaction results underwent square-root transformation
prior to statistical analysis.
RESULTS
Drug consumption and serum level measurements.
Average mouse weight was 20 g, and average chow con-
sumed was 3.6 g/day/mouse. Hence, doses consumed were
24 mg/kg/day for group 6 and 12 mg/kg/day for groups 2
and 5 (Table 1). The corresponding mean serum drug levels
(g/ml) were 2.09  0.09 versus 1.03  0.15 (p  0.001)
in these groups, respectively. Sera of mice from untreated
groups were negative for drug.
Cholesterol levels. The total serum cholesterol levels did
not differ significantly among the six groups. Mean choles-
terol levels (mg/dl) were: 365.9 21.0, 421.8 32.0, 451.9
 35.6, 390.1  41.2, 436.9  79.1, and 480.8  23.1 in
groups 1 to 6, respectively.
Detection of CMV DNA by PCR. As shown in Figure 1,
the mean mouse CMV DNA in salivary glands, a PCR-
derived index of the number of viral particles present in the
tissue, was: 2.58 1.0 in the CMV-infected/no drug group,
4.74  1.38 in the CMV-infected/12 mg/kg dose group,
and 6.51  1.64 in the CMV-infected/24 mg/kg dose
treatment group (p trend  0.050). A dose-response curve
was evident; highest drug level was associated with highest
viral load. Sham-infected mice were negative for CMV
DNA (group 3) (Table 1). All positive and negative controls
worked as expected, and all samples were positive when
entered into a PCR with primers for the apoB gene,
indicating adequate quality of DNA.
Mouse anti-CMV IgG antibody titers. Figure 2 shows
mean anti CMV IgG antibody titers in serum were: 602.4
 93.4 in the CMV-infected/no drug group, 1,031.3 
154.6 in the CMV-infected/12 mg/kg dose group, and
1,264.7  232.7 in the CMV-infected/24 mg/kg dose
Figure 1. Mouse cytomegalovirus (CMV) deoxyribonucleic acid (DNA) concentration in mouse salivary glands. This value (which underwent square root
transformation before statistical analysis) was taken as a polymerase chain reaction (PCR)-derived index of the number of viral particles present in the tissue.
The results show a dose-response curve, with highest drug level associated with highest viral load. All sham-infected mice were negative for CMV DNA.
The gene targeted for PCR amplification was mouse CMV IE1 exon 4. *p  0.05 vs. no drug treatment group.
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group (p trend 0.025). Sham-infected mice were negative
for anti-CMV IgG antibodies.
Quantification of atherosclerotic lesions. Analysis in-
cluded 11 or 12 samples from each of the six groups (Table
1). Figure 3 shows mean lesion area (m2) was 6,096.5 
1,837 in the noninfected/no-drug group, 11,215.8  1,369
in the noninfected/12 mg/kg dose group, 6,036.5  154 in
the sham-infected/no-drug group, 6,947.8  1,166 in the
CMV-infected/no-drug group, 11,785.7  1,512 in the
infected/12 mg/kg dose group, and 12,514.2  1,252 in the
infected/24 mg/kg dose group (p trend 0.001). Drug
treatment consistently increased lesion size: by 84% in the
noninfected group (Fig. 4) and by 70% and by 80% in the
CMV-infected low-dose and high-dose groups, respec-
tively. Thus, significant differences were detected between
each individual drug-treated group (groups 2, 5, and 6)
(Table 1) when compared with each individual nontreated
group (groups 1, 3, and 4) (Table 1). In this study infection
with CMV did not increase lesion size.
Cytokine concentrations. Interferon-gamma, TNF, and
IL-6 were undetectable in the serum of all six groups (data
not shown). However, all controls worked as expected,
indicating adequate test quality.
DISCUSSION
Previous investigations from our laboratory, described in the
introduction, demonstrated that aspirin, a nonselective
COX inhibitor, inhibits in vitro CMV replication in coro-
nary artery SMCs by preventing CMV-induced ROS gen-
eration. This latter effect was also shared by indomethecin,
another nonselective COX inhibitor, and by the selective
COX-2 inhibitor NS-398 (11).
Cyclooxygenase-2, one of two isoforms of COX (16), is
Figure 2. Anti-mouse cytomegalovirus (CMV) immunoglobulin G (IgG) antibody titer in mice sera. All mice were infected with the same concentration
of virus. Cytomegalovirus antibody titers increased with increasing dose of the cyclooxygenase-2 inhibitor, compatible with a drug-induced increase in viral
load seen in Figure 1. All sham-infected mice were negative for anti-CMV IgG antibodies. *p  0.025 vs. no drug treatment group; **p  0.015 vs. no
drug treatment group.
Figure 3. Atherosclerotic lesion area. Selective cyclooxygenase-2 inhibition consistently increased lesion size: by 84% in the noninfected group, and by 70%
and by 80% in the cytomegalovirus (CMV)-infected low-dose and high-dose groups respectively. In this study, infection with CMV did not increase lesion
size. *p  0.013 vs. no drug treatment/no inoculum group; #p  0.01 vs. no drug treatment/no inoculum group; §p  0.01 vs. no drug treatment/sham
infection group; &p  0.02 vs. no drug treatment group/CMV infection group; p  0.05 vs. no drug treatment group/CMV infection group.
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induced by mitogens, cytokines, certain inflammatory
agents (17), and, as we showed, CMV infection (7,10,11). It
is the isoform thought to promote inflammation.
Cyclooxygenase-1 is constitutively expressed in most tissues
and serves as the “housekeeping” isoform; its presence in
platelets leads to platelet aggregation via COX-1-mediated
thromboxane A2 (17) production.
Because of the critical role of CMV-induced ROS
generation in both viral and cellular gene expression, and
because inflammation plays a critical role in atherogenesis,
we considered that COX-2 might constitute a therapeutic
target whereby its inhibition would decrease CMV replica-
tion in vivo and inhibit inflammatory changes that might
contribute to atherogenesis. Therefore, the present investi-
gation was initiated to determine the validity of two
hypotheses: 1) selective COX-2 inhibition, through the mech-
anisms responsible for its in vitro antiviral effects, reduces CMV
replication in vivo; and 2) selective COX-2 inhibition, through
its anti-inflammatory activity, decreases atherosclerosis devel-
opment independent of infection.
To our surprise, we found just the opposite. Regarding
the first hypothesis, selective COX-2 inhibition with MF-
tricyclic increased viral load in a dose-dependent fashion,
with the highest dose increasing viral load by about 100%
(Fig. 1). We also found a parallel dose-response effect of
MF-tricyclic on anti-CMV antibody titers (Fig. 2), suggest-
ing that the increase in viral load found in the treated
animals represented a biologically relevant change.
In the experimental design we employed for this investi-
gation, CMV infection itself had no effect on lesion size.
Therefore, we were unable to determine whether selective
COX-2 inhibition diminishes CMV-induced increase in
atherosclerosis development. In two separate studies we
found that CMV infection increases lesion development in
apoE knockout mice (4,6). The differences between this and
the prior publications are undoubtedly due to the fact that in
the present study we employed a brief three-week period
between infection and sacrifice, whereas in the previous
studies sacrifice occurred 14 weeks after infection. Three
weeks appears too brief a time for any pro-atherosclerotic
effects of CMV to become manifest.
The result of the study exploring the validity of the
second hypothesis we examined was also unexpected. Lesion
analysis showed that selective COX-2 inhibition with MF-
tricyclyic increases atherosclerotic lesion area (Figs. 3 and 4).
It should be noted that lesions in this particular model, in
which apoE knockout mice were sacrificed at only 11 weeks
of age and after only 3 weeks on the selective COX-2
inhibitor, were very early lesions. Therefore, our results are
probably more relevant to lesion initiation.
Selective COX-2 inhibition and CMV replication.
Although initially surprising, upon further reflection the
contrast between in vitro and in vivo COX-2 inhibition
effects should have been anticipated. The in vitro experi-
ment consists of a simple system, one cell type and only two
variables: 1) virus and 2) drug treatment. In this system,
drug-induced selective COX-2 inhibition exerted a signif-
icant antiviral effect. The putative mechanisms, relating to
inhibition of ROS generation, have been discussed. The in
vivo situation, however, is considerably more complex, with
multiple possible consequences of drug activity. For in-
stance, COX-2 inhibition has, in vivo, potent anti-
Figure 4. Oil red O staining of atherosclerotic lesions in the aorta. Representative photomicrographs (10 magnification) of the lesions present in two
uninfected mice. (A) Untreated with MF-tricyclic; (B) treated with MF-tricyclic, 12 mg/kg/day. The arrows point to some of the aortic valve leaflets,
indicating that the sections employed for measuring lesion size are located, as is traditional, at the root of the aorta.
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inflammatory effects. These effects include hindering re-
cruitment of neutrophils to sites of injury (18) and
interfering with monocyte recruitment (19). Both neutro-
phils and monocytes, components of the innate immune
response, function as the initial host defense response to the
invading pathogen and contain infection until more efficient
but slower adaptive immune responses develop.
Cyclooxygenase-2 inhibition of the innate immune response
probably contributes to increasing in vivo susceptibility to
viral infection. In addition, COX-2 participates in the
synthesis of cyclopentenone prostaglandins (PG) (20), po-
tent inhibitors of viral replication (21). This COX-2 activity
provides another possible mechanism for increased viral
replication following COX-2 inhibition.
We are not familiar with any evidence that COX-2
inhibition alters the cellular component of the adaptive
immune response. Our results suggest that COX-2 inhibi-
tion probably does not interfere with the humoral compo-
nent, as we observed higher anti-CMV IgG titers of the
mice treated with the COX-2 inhibitor, which paralleled
their higher viral load.
Interferon-gamma was undetectable in the serum of all
six groups in the current study. An earlier report by our
group showed CMV induces IFN in mouse serum (22). In
that study mice were infected at two weeks of age and
sacrificed four weeks later. Because it is well known that
immune responses of neonates evolve markedly over the first
weeks and months of life, we can only speculate that
two-week-old mice react differently to infection than do
adult mice. Such age-related differences in responses could
account for the different IFN responses to infection we
observed between the two studies.
Selective COX-2 inhibition and atherosclerosis. The
second unanticipated finding of our study was that in
contrast to our hypothesis, selective COX-2 inhibition
actually increased early lipid aortic accumulation in the apoE
knockout mice. This raises a major conundrum: why should
an anti-inflammatory drug accelerate the initiation of ath-
erosclerosis, a disease recognized as having a major inflam-
matory component?
Recent studies have demonstrated a complex role for
COX-2 in inflammation, in that the enzyme appears to
possess not only its well-known inflammatory activity, but
also anti-inflammatory properties (23–25). This latter activ-
ity resides in a previously unrecognized role of COX-2 in
the resolution phase of the inflammatory response.
Some mechanistic insight relevant to these studies is
provided by the investigation of Gilroy et al. (26). They
showed in a rat model of inflammation that there are two
phases of COX-2 expression: an early phase associated with
high levels of PGE2 synthesis and a later phase associated
with a second peak that, paradoxically, coincides with
inflammatory resolution. This second peak is associated with
minimal PGE2 synthesis and high levels of both PGD2 and
PGJ2.
Compatible with this concept of dual time-delayed peaks
of COX-2 that exert opposite effects on inflammation are
the findings that the selective COX-2 inhibitor NS-398 and
the nonselective COX inhibitor indomethacin inhibit in-
flammation when given at the early phase of inflammation,
but exacerbate inflammation when given at the late phase
(20). Consequently, Colville-Nash and Gilroy (27) sug-
gested that COX-2 is pro-inflammatory early in inflamma-
tion, but facilitates inflammatory resolution later.
These findings, suggesting a dual role for COX-2 in
inflammation and inflammation resolution, have been dem-
onstrated only in rodent models, and no evidence is yet
available that such a dual role is present in humans.
Nonetheless, this concept may explain our unexpected
results. The ApoE deficient mice develop spontaneous
atherosclerosis. Significant inflammatory changes in the
aorta are detected at five to six weeks of age (28). At eight
weeks (the age of our mice at the beginning of the study)
there is well-established inflammation of the arterial wall.
We initiated selective COX-2 inhibition at a time of
ongoing vessel wall inflammation, a time that COX-2,
according to this concept, is anti-inflammatory and, there-
fore, when its inhibition would exacerbate atherogenesis.
Recently, studies in mice suggested that selective COX-2
inhibition, through inhibition of PGI2 activity, may exert
pro-proliferative vascular effects. Thus, Cheng et al. (29)
demonstrated that mice genetically deficient in the PGI2
receptor exhibit an increased proliferative response to vas-
cular injury, an effect that could contribute to a gradual
increase in atherosclerotic lesion size through enhanced
proliferation of vascular SMCs.
Potential deleterious effects of selective COX-2 inhibi-
tion on the course of atherosclerosis in humans were sug-
gested by the demonstration in patients with rheumatoid
arthritis that rofecoxib, a selective COX-2 inhibitor, was
associated with a higher number of acute coronary events
than occurred in patients treated with naproxen, a nonse-
lective COX inhibitor (30). Moreover, a meta-analysis (with
all the limitations inherent in such an analysis) of several
published studies employing selective COX-2 inhibitors
suggested that such treatment increased the incidence of
myocardial infarction (31). Another examination of the
same issue concluded that whereas there was a significant
increase in cardiovascular events when rofecoxib was com-
pared with naproxen, there was no evidence of excess
cardiovascular events for rofecoxib relative to either placebo
or to non-naproxen nonselective COX inhibitors (32).
The mechanisms responsible for precipitation of acute
coronary events derive from plaque instability and plaque
rupture. Following rupture, the highly thrombogenic plaque
core is exposed to blood within the vessel lumen, resulting in
platelet aggregation, thrombus formation, and acute vascu-
lar occlusion (13). Thus, any deleterious effects of selective
COX-2 inhibitors on the course of atherosclerosis could
involve three separate processes: 1) a proinflammatory effect
that accelerates the initiation and chronic progression of the
atherogenesis process, and that may induce plaque instabil-
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ity and rupture; 2) a procoagulant effect (induced by inhibi-
tion of COX-2–mediated expression of the highly anti-
thrombotic PGI2 without concomitant reduction of COX-
1–mediated expression of the highly thrombotic
thromboxane A2 (31) that precipitates an acute coronary
syndrome; and 3) a pro-proliferative effect that could increase
lesion size through accumulation of SMCs.
Of additional relevance is the finding that indomethacin,
a nonselective COX inhibitor, significantly reduced athero-
sclerosis in mice (33). Indomethacin is more potent in
inhibiting COX-1 compared with COX-2 (34). Therefore,
the data taken in their entirely, suggest that COX-1 has
pro-atherosclerotic activity, whereas COX-2 is not pro-
atherosclerotic and may even have a protective effect; con-
versely, inhibitors of COX-1 appear to protect against
atherosclerosis, and selective inhibitors of COX-2 may have
deleterious consequences.
These concepts, however, must still be considered hy-
potheses to be validated, as other data relating to selective
COX-2 inhibition suggest possible anti-atherogenesis ef-
fects (through inhibition of inflammation) and a plaque
stabilization effect (through inhibition of PGE2-dependent
matrix metalloproteinase expression by macrophages within
plaques) (35). Moreover, our results may be model-, therapy
duration-, and drug-specific. For example, Pratico et al. (33)
used an low-density lipoprotein receptor knockout mouse,
employed the selective COX-2 inhibitor nimesulide, and
sacrificed mice at 26 weeks of age compared with our 11
weeks of age; they found the COX-2 inhibitor exerted no
effect on the rate of atherogenesis. Although these caveats
relating to the conclusions of our investigation must be
acknowledged, the important fact emerging from our study
is that a selective COX-2 inhibitor, under the experimental
conditions we studied, can increase early atherosclerosis
lesion formation.
In conclusion, the results of this investigation raise
disturbing questions about possible adverse effects deriving
from chronic use of selective COX-2 inhibitors on suscep-
tibility to viral infection and on early atherosclerosis lesion
development. However, extrapolation of our results ob-
tained in a mouse model to humans taking COX-2 inhib-
itors may not necessarily be valid. Moreover, the doses given
to the mice resulted in serum levels that were at least four
times higher (using the low dose of the COX-2 inhibitor,
12 mg/kg/day), on a molar basis, than those seen in patients
receiving the usual clinical dose of rofecoxib (25 mg once
daily).
Because of the importance of the implications of the
conclusions deriving from our investigation, and because of
the intrinsic limitations of an animal model outlined above,
the conclusions must be regarded as tentative and hypoth-
esis generating. Our results emphasize the critical need for
more information regarding the relative biologic roles of
both COX isoforms, and in particular their roles in inflam-
mation, in resistance to infection, and in atherogenesis.
Acknowledgments
The authors would like to thank Ms. Pauline Luk form
Merck Frosst Canada, and Mr. Michael Siddon from
BioServe Biotechnologies, Ltd., Laurel, Maryland, for out-
standing technical help.
Reprint requests and correspondence: Dr. Stephen E. Epstein,
Cardiovascular Research Institute, Washington Hospital Center,
110 Irving Street NW, Suite 4B-1, Washington, DC 20010.
E-mail: stephen.epstein@medstar.net.
REFERENCES
1. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging
mechanistic paradigms. Circulation 1999;100:20–8.
2. Zhu J, Quyyumi AA, Norman JE, et al. Cytomegalovirus in the
pathogenesis of atherosclerosis: the role of inflammation as reflected by
elevated C-reactive protein levels. J Am Coll Cardiol 1999;34:1738–
43.
3. Thom DM, Grayston JT, Siscovitch DS, et al. Association of prior
infection with Chlamydia pneumoniae and angiographically demon-
strated coronary artery disease. JAMA 1992;268:68–72.
4. Burnett MS, Gaydos CA, Madico GE, et al. Atherosclerosis in apoE
knockout mice infected with multiple pathogens. J Infect Dis 2001;
183:226–31.
5. Berencsi K, Endresz V, Klurfeld D, et al. Early atherosclerotic plaques
in the aorta following cytomegalovirus infection of mice. Cell Adhes
Commun 1998;5:39–47.
6. Hsich E, Zhou YF, Paigen B, et al. Cytomegalovirus infection
increases development of atherosclerosis in Apolipoprotein-E knock-
out mice. Atherosclerosis 2001;156:23–8.
7. Speir E, Shibutani T, Yu ZX, et al. Role of reactive oxygen interme-
diates in cytomegalovirus gene expression and in response of human
smooth muscle cells to viral infection. Circ Res 1996;79:1143–52.
8. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as
apparently widely used messengers in the activation of the NF-kappa
B transcription factor and HIV-1. EMBO J 1991;10:2247–58.
9. Sambucetti LC, Cherrington JM, Wilokinson GW, Mocarski ES.
NF-kappa B activation of the cytomegalovirus enhancer is mediated by
a viral transactivator and by T cell stimulation. EMBO J 1998;8:
4251–8.
10. Shibutani T, Johnson TM, Yu Z-X, Ferrans VJ, Moss J, Epstein SE.
Pertussis toxin-sensitive G proteins as mediators of the signal trans-
duction pathways activated by cytomegalovirus infection of smooth
muscle cells. J Clin Invest 1997;100:2054–61.
11. Speir E, Yu ZX, Ferrans VJ, et al. Aspirin attenuates cytomegalovirus
infectivity and gene expression mediated by cyclooxygenase-2 in
coronary artery smooth muscle cells. Circ Res 1998;83:210–6.
12. Lefkowith JB. Cyclooxygenase-2 specificity and its clinical implica-
tions. Am J Med 1999;106:43S–50S.
13. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med
1999;340:115–26.
14. Black SC, Brideau C, Cirino M, et al. Differential effect of a selective
cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in
conscious volume-depleted dogs. J Cardiovasc Pharmacol 1998;32:
686–94.
15. Paigen B, Morrow A, Holmes PA, et al. Quantitative assessment of
atherosclerotic lesions in mice. Atherosclerosis 1987;68:231–40.
16. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide
H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:
33157–60.
17. Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1
and -2. Adv Immunol 1996;62:167–215.
18. Wilgus TA, Ross MS, Parrett ML, et al. Topical application of a
selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous
inflammation. Prostaglandins Other Lipid Mediat 2000;62:367–84.
19. Langenbach R, Loftin C, Lee C, Tiano H. Cyclooxygenase knockout
mice: models for elucidating isoform-specific functions. Biochem
Pharmacol 1999;58:1237–46.
1818 Rott et al. JACC Vol. 41, No. 10, 2003
COX-2 Inhibition, Atherogenesis, and CMV Replication May 21, 2003:1812–9
20. Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxy-
genase may have anti-inflammatory properties. Nat Med 1999;5:698–
701.
21. Santoro MG. Antiviral activity of cyclopentenone prostanoids. Trends
Microbiol 1997;5:276–81.
22. Rott D, Zhu J, Brunett MS, et al. Serum of cytomegalovirus infected
mice induces monocyte chemoattractant protein-1 expression by en-
dothelial cells. J Infect Dis 2001;184:1109–13.
23. Langenbach R, Loftin C, Lee C, et al. Cyclooxygenase knockout mice:
models for elucidating isoform-specific functions. Biochem Pharmacol
1999;58:1237–46.
24. Morteau O. Prostaglandins and inflammation: the cyclooxygenase
controversy. Arch Immunol Ther Exp 2000;48:473–80.
25. Smith WL, Langenbach R. Why there are two cyclooxygenase
isoenzymes. J Clin Inv 2001;107:1491–5.
26. Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of
inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2)
in acute inflammation. Eur J Pharmacol 1998;355:211–7.
27. Colville-Nash PR, Gilroy DW. COX-2 and the cyclopentenone
prostaglandins—a new chapter in the book of inflammation? Prosta-
glandins Other Lipid Mediat 2000;62:33–43.
28. Breslow JL. Mouse models of atherosclerosis. Science 1996;272:
685–8.
29. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the
cardiovascular response to thromboxane A2. Science 2002;296:539–41.
30. Bombardier C, Laine L, Reicin A, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in patients with
rheumatoid arthritis. N Engl J Med 2000;343:1520–8.
31. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events
associated with selective COX-2 inhibitors. JAMA 2001;286:954–9.
32. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic
events in controlled, clinical trials of rofecoxib. Circulation 2001;104:
2280–8.
33. Pratico D, Tillmann C, Zhang ZB, et al. Acceleration of athero-
genesis by COX-1-dependent prostanoid formation in low density
lipoprotein receptor knockout mice. Proc Natl Acad Sci USA
2001;98:3358 –63.
34. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity
of nonsteroidal anti-inflammatory drugs as inhibitors of constitu-
tive and inducible cyclooxygenase. Proc Natl Acad Sci USA
1994;90:11693–7.
35. Cipollone F, Prontera C, Pini B, et al. Over expression of functionally
coupled cyclooxygenase-2 and prostaglandin in symptomatic athero-
sclerotic plaques as a basis of prostaglandin E2-dependent plaque
instability. Circulation 2001;104:921–7.
1819JACC Vol. 41, No. 10, 2003 Rott et al.
May 21, 2003:1812–9 COX-2 Inhibition, Atherogenesis, and CMV Replication
